Dentsply Sirona, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Dentsply Sirona, Inc.
While Amicus will transfer the gene therapy portfolio’s R&D risk to Caritas, it retains a financial interest in many of the spinout’s programs. Pompe candidate AT-GAA accepted for FDA review.
At $1.2 billion, Q4 device financing was the second-lowest quarter of 2015; M&A dollar volume was also low, but included multiple deals across various cardiovascular markets. Diagnostics financing was also down in Q4, totaling $403 million; acquisitions were worth $441 million.
Medtech M&A activity has been on the rise for several years along with a surge in the number of higher-valued mega-deals, those worth at least $1 billion. Yet a survey of all deals with known values indicates that median deal value has actually declined.
There were 225 medtech M&A deals in 2015, down from 269 in 2014, according to Clinica's M&A Tracker. The in vitro diagnostics sector continues to be the most popular for transactions.
- Consumables, Central Supplies
- Diagnostic Imaging Equipment & Supplies
- Other Names / Subsidiaries
- Astra Tech AB
- DENTSPLY International, Inc.
- Sirona Dental Systems, Inc.
- Wellspect Healthcare